Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH.
Schramm A, et al. Among authors: versteeg r.
Br J Cancer. 2012 Oct 9;107(8):1409-17. doi: 10.1038/bjc.2012.391.
Br J Cancer. 2012.
PMID: 23047593
Free PMC article.